-
5
-
9
Journal Article
by Champiat, Stéphane Dercle, Laurent Ammari, Samy Massard, Christophe Hollebecque, Antoine Postel-Vinay, Sophie Chaput, Nathalie Eggermont, Alexander Marabelle, Aurélien Soria, Jean-Charles Ferté, Charles Published in Clinical cancer research (15.04.2017)“...While immune checkpoint inhibitors are disrupting the management of patients with cancer, anecdotal occurrences of rapid progression (i.e., hyperprogressive...”
-
10
Journal Article
by Taube, Janis M Klein, Alison Brahmer, Julie R Xu, Haiying Pan, Xiaoyu Kim, Jung H Chen, Lieping Pardoll, Drew M Topalian, Suzanne L Anders, Robert A Published in Clinical cancer research (01.10.2014)“...Immunomodulatory drugs differ in mechanism-of-action from directly cytotoxic cancer therapies. Identifying factors predicting clinical response could guide...”
-
11
Journal Article
by Gainor, Justin F Shaw, Alice T Sequist, Lecia V Fu, Xiujun Azzoli, Christopher G Piotrowska, Zofia Huynh, Tiffany G Zhao, Ling Fulton, Linnea Schultz, Katherine R Howe, Emily Farago, Anna F Sullivan, Ryan J Stone, James R Digumarthy, Subba Moran, Teresa Hata, Aaron N Yagi, Yukako Yeap, Beow Y Engelman, Jeffrey A Mino-Kenudson, Mari Published in Clinical cancer research (15.09.2016)“...PD-1 inhibitors are established agents in the management of non-small cell lung cancer (NSCLC); however, only a subset of patients derives clinical benefit. To...”
-
12
Journal Article
by Marcus, Leigh Lemery, Steven J Keegan, Patricia Pazdur, Richard Published in Clinical cancer research (01.07.2019)“...The FDA approved pembrolizumab on May 23, 2017, for the treatment of adult and pediatric patients with unresectable or metastatic, microsatellite...”
-
13
Journal Article
by Kato, Shumei Goodman, Aaron Walavalkar, Vighnesh Barkauskas, Donald A Sharabi, Andrew Kurzrock, Razelle Published in Clinical cancer research (01.08.2017)“...Checkpoint inhibitors demonstrate salutary anticancer effects, including long-term remissions. PD-L1 expression/amplification, high mutational burden, and...”
-
14
Journal Article
by Jiao, Shiping Xia, Weiya Yamaguchi, Hirohito Wei, Yongkun Chen, Mei-Kuang Hsu, Jung-Mao Hsu, Jennifer L Yu, Wen-Hsuan Du, Yi Lee, Heng-Huan Li, Chia-Wei Chou, Chao-Kai Lim, Seung-Oe Chang, Shih-Shin Litton, Jennifer Arun, Banu Hortobagyi, Gabriel N Hung, Mien-Chie Published in Clinical cancer research (15.07.2017)“...To explore whether a cross-talk exists between PARP inhibition and PD-L1/PD-1 immune checkpoint axis, and determine whether blockade of PD-L1/PD-1 potentiates...”
-
15
Journal Article
by Ren, Jiangtao Liu, Xiaojun Fang, Chongyun Jiang, Shuguang June, Carl H Zhao, Yangbing Published in Clinical cancer research (01.05.2017)“...Using gene-disrupted allogeneic T cells as universal effector cells provides an alternative and potentially improves current chimeric antigen receptor (CAR)...”
-
16
Journal Article
by Freeman-Keller, Morganna Kim, Youngchul Cronin, Heather Richards, Allison Gibney, Geoffrey Weber, Jeffrey S Published in Clinical cancer research (15.02.2016)“...Retrospective analysis of irAEs in melanoma patients treated with nivolumab. Data were pooled from 148 patients (33 resected, 115 unresectable) treated with...”
-
17
Journal Article
by Dong, Zhong-Yi Zhong, Wen-Zhao Zhang, Xu-Chao Su, Jian Xie, Zhi Liu, Si-Yang Tu, Hai-Yan Chen, Hua-Jun Sun, Yue-Li Zhou, Qing Yang, Jin-Ji Yang, Xue-Ning Lin, Jia-Xin Yan, Hong-Hong Zhai, Hao-Ran Yan, Li-Xu Liao, Ri-Qiang Wu, Si-Pei Wu, Yi-Long Published in Clinical cancer research (15.06.2017)“...Although clinical studies have shown promise for targeting programmed cell death protein-1 (PD-1) and ligand (PD-L1) signaling in non-small cell lung cancer...”
-
18
Journal Article
by YU, Helena A ARCILA, Maria E REKHTMAN, Natasha SIMA, Camelia S ZAKOWSKI, Maureen F PAO, William KRIS, Mark G MILLER, Vincent A LADANYI, Marc RIELY, Gregory J Published in Clinical cancer research (2013)“...All patients with EGF receptor (EGFR)-mutant lung cancers eventually develop acquired resistance to EGFR tyrosine kinase inhibitors (TKI). Smaller series have...”
-
19
Journal Article
by Burstein, Matthew D Tsimelzon, Anna Poage, Graham M Covington, Kyle R Contreras, Alejandro Fuqua, Suzanne A W Savage, Michelle I Osborne, C Kent Hilsenbeck, Susan G Chang, Jenny C Mills, Gordon B Lau, Ching C Brown, Powel H Published in Clinical cancer research (01.04.2015)“...Genomic profiling studies suggest that triple-negative breast cancer (TNBC) is a heterogeneous disease. In this study, we sought to define TNBC subtypes and...”
-
20
Journal Article
by Ballard, Peter Yates, James W T Yang, Zhenfan Kim, Dong-Wan Yang, James Chih-Hsin Cantarini, Mireille Pickup, Kathryn Jordan, Angela Hickey, Mike Grist, Matthew Box, Matthew Johnström, Peter Varnäs, Katarina Malmquist, Jonas Thress, Kenneth S Jänne, Pasi A Cross, Darren Published in Clinical cancer research (15.10.2016)“...Approximately one-third of patients with non-small cell lung cancer (NSCLC) harboring tumors with EGFR-tyrosine kinase inhibitor (TKI)-sensitizing mutations...”
Are you a member of Bonn University? Yes: Then connect to the University network via VPN client in order to access the licensed contents. No: You can then access licensed contents using the Service Pcs within the ULB Bonn. Bitte buchen Sie den Arbeitsplatz 'Service-PC o. Scanner'
Lesen Sie bitte unsere aktuellen Informationen zur ULB im geschützten Betrieb.
